iRhythm Technologies - IRTC Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iRhythm Technologies in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRTC shares.
View IRTC analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 1 year price objectives for iRhythm Technologies' shares. Their IRTC share price forecasts range from $105.00 to $190.00. On average, they expect the company's share price to reach $146.36 in the next year. This suggests a possible upside of 27.2% from the stock's current price.
View analysts price targets for IRTC or view top-rated stocks among Wall Street analysts.

iRhythm Technologies' stock was trading at $93.67 at the start of the year. Since then, IRTC shares have increased by 22.8% and is now trading at $115.05.
View the best growth stocks for 2023 here.

iRhythm Technologies saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 2,130,000 shares, an increase of 6.0% from the February 13th total of 2,010,000 shares. Based on an average daily volume of 326,200 shares, the days-to-cover ratio is currently 6.5 days.
View iRhythm Technologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our IRTC earnings forecast.

iRhythm Technologies, Inc. (NASDAQ:IRTC) released its quarterly earnings data on Thursday, February, 23rd. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.04. The company had revenue of $112.62 million for the quarter, compared to analysts' expectations of $110.62 million. iRhythm Technologies had a negative net margin of 28.27% and a negative trailing twelve-month return on equity of 35.85%.

ETFs with the largest weight of iRhythm Technologies (NASDAQ:IRTC) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Robotics & Automation ETF (ROBO), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC) and AI Powered Equity ETF (AIEQ).

iRhythm Technologies issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $475.00 million-$485.00 million, compared to the consensus revenue estimate of $485.60 million.

20 employees have rated iRhythm Technologies Chief Executive Officer Kevin M. King on Glassdoor.com. Kevin M. King has an approval rating of 91% among the company's employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other iRhythm Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Teladoc Health (TDOC), Trade Desk (TTD), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and Boeing (BA).

(IRTC) raised $76 million in an initial public offering (IPO) on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

iRhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

iRhythm Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Sands Capital Management LLC (8.86%), Artisan Partners Limited Partnership (4.64%), LTS One Management LP (4.25%), Mackenzie Financial Corp (4.14%), Alliancebernstein L.P. (4.07%) and JPMorgan Chase & Co. (3.76%). Insiders that own company stock include Daniel G Wilson, David A Vort, David A Vort, Douglas Devine, Kevin M King, Mark J Day, Merz Cathleen Noel Bairey, Patrick Michael Murphy, Quentin S Blackford, Ralph Snyderman and Raymond W Scott.
View institutional ownership trends.

Shares of IRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRTC stock can currently be purchased for approximately $115.05.

iRhythm Technologies (NASDAQ:IRTC) has a market capitalization of $3.48 billion and generates $410.92 million in revenue each year. The company earns $-116,150,000.00 in net income (profit) each year or ($3.89) on an earnings per share basis.

The company employs 1,793 workers across the globe.

iRhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The official website for the company is www.irhythmtech.com. The company can be reached via phone at (415) 632-5700 or via email at investors@irhythmtech.com.